Voyager Therapeutics (VYGR) Files $86.25M Common Stock IPO

Voyager Therapeutics, Inc. (Nasdaq: VYGR) filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The proposed maximum offering amount is $86.25 million. Voyager Therapeutics intends to list its common stock on the Nasdaq under the ticker symbol "VYGR."

Underwriters are Cowen and Company, Piper Jaffray, Nomura, and Wedbush PacGrow.

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system, or CNS.

The company continued, We focus on CNS diseases where we believe that an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. We have created a product engine that enables us to engineer, optimize, manufacture and deliver our AAV-based gene therapies that have the potential to provide durable efficacy following a single administration directly to the CNS. Our product engine has rapidly generated programs for five CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis, or a form of the disease caused by a single gene mutation; Friedreich's ataxia; Huntington's disease; and spinal muscular atrophy. Our most advanced clinical candidate, VY-AADC01, is being evaluated for the treatment of advanced Parkinson's disease in an open-label, Phase 1b clinical trial with the goal of generating human proof-of-concept data in the second half of 2016. Our founders and members of our management team have extensive experience in drug discovery and development and have pioneered significant advances within the fields of AAV gene therapy and neuroscience.

You May Also Be Interested In

• Agility Robotics to go public via $2.5B SPAC merger
• SEC probing popular type of private equity fund as it steps up industry scrutiny - Reuters
• MoonLake prices $200 million public offering at $20 per share